Bayer Aktiengesellschaft (BAYRY)
- Previous Close
6.40 - Open
6.34 - Bid 6.39 x 40000
- Ask 6.42 x 40000
- Day's Range
6.32 - 6.43 - 52 Week Range
4.79 - 8.58 - Volume
213,721 - Avg. Volume
678,885 - Market Cap (intraday)
27.185B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.93 - Earnings Date Aug 6, 2025
- Forward Dividend & Yield 0.03 (0.49%)
- Ex-Dividend Date Apr 29, 2025
- 1y Target Est
8.59
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
www.bayer.com90,885
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BAYRY
View More
Performance Overview: BAYRY
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAYRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAYRY
View MoreValuation Measures
Market Cap
27.18B
Enterprise Value
63.66B
Trailing P/E
--
Forward P/E
5.03
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.48
Price/Book (mrq)
0.70
Enterprise Value/Revenue
1.22
Enterprise Value/EBITDA
7.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.98%
Return on Assets (ttm)
2.55%
Return on Equity (ttm)
-9.49%
Revenue (ttm)
46.58B
Net Income Avi to Common (ttm)
-3.25B
Diluted EPS (ttm)
-0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
4.02B
Total Debt/Equity (mrq)
120.88%
Levered Free Cash Flow (ttm)
5.12B
Research Analysis: BAYRY
View MoreResearch Reports: BAYRY
View MoreBayer Earnings: First Quarter in Line With Previous Guidance, Potential Green Shoots Ahead
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer's Near-Term Outlook Dominated by Generic Pressures and Crop Science Uncertainty
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer's Near-Term Outlook Dominated by Generic Pressures and Crop Science Uncertainty
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer's Near-Term Outlook Dominated by Generic Pressures and Crop Science Uncertainty
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target